HRP20110242T1 - Formulacija s fuzijskim proteinom glp-1-fc - Google Patents
Formulacija s fuzijskim proteinom glp-1-fc Download PDFInfo
- Publication number
- HRP20110242T1 HRP20110242T1 HR20110242T HRP20110242T HRP20110242T1 HR P20110242 T1 HRP20110242 T1 HR P20110242T1 HR 20110242 T HR20110242 T HR 20110242T HR P20110242 T HRP20110242 T HR P20110242T HR P20110242 T1 HRP20110242 T1 HR P20110242T1
- Authority
- HR
- Croatia
- Prior art keywords
- stable solution
- solution formulation
- formulation according
- concentration
- glp
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims abstract 19
- 239000000203 mixture Substances 0.000 title claims abstract 19
- 108020001507 fusion proteins Proteins 0.000 title claims abstract 8
- 102000037865 fusion proteins Human genes 0.000 title claims abstract 8
- 239000000243 solution Substances 0.000 claims abstract 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 5
- 229930195725 Mannitol Natural products 0.000 claims abstract 5
- 239000000594 mannitol Substances 0.000 claims abstract 5
- 235000010355 mannitol Nutrition 0.000 claims abstract 5
- 239000007979 citrate buffer Substances 0.000 claims abstract 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 4
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract 4
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 4
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94885507P | 2007-07-10 | 2007-07-10 | |
PCT/US2008/069473 WO2009009562A2 (en) | 2007-07-10 | 2008-07-09 | Glp-1-fc fusion protein formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110242T1 true HRP20110242T1 (hr) | 2011-05-31 |
Family
ID=39870243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110242T HRP20110242T1 (hr) | 2007-07-10 | 2011-04-04 | Formulacija s fuzijskim proteinom glp-1-fc |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100196405A1 (ru) |
EP (1) | EP2175834B8 (ru) |
JP (1) | JP2010533197A (ru) |
KR (1) | KR20100020516A (ru) |
CN (1) | CN101730523A (ru) |
AT (1) | ATE499088T1 (ru) |
AU (1) | AU2008275180A1 (ru) |
BR (1) | BRPI0813699B1 (ru) |
CA (1) | CA2691695C (ru) |
DE (1) | DE602008005155D1 (ru) |
EA (1) | EA201070121A1 (ru) |
HK (1) | HK1141237A1 (ru) |
HR (1) | HRP20110242T1 (ru) |
MX (1) | MX2010000380A (ru) |
NZ (1) | NZ582480A (ru) |
RS (1) | RS52378B (ru) |
UA (1) | UA97673C2 (ru) |
WO (1) | WO2009009562A2 (ru) |
ZA (1) | ZA201000149B (ru) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2519031C1 (ru) * | 2010-01-19 | 2014-06-10 | Ханми Сайенс Ко., Лтд. | Жидкие препаративные формы для длительно действующего конъюгата g-csf |
JP5800527B2 (ja) * | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法 |
CN102533655A (zh) * | 2010-12-21 | 2012-07-04 | 青岛黄海制药有限责任公司 | 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法 |
SG195258A1 (en) | 2011-06-10 | 2013-12-30 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
PE20181268A1 (es) | 2011-06-17 | 2018-08-03 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo |
WO2014014206A1 (en) * | 2012-07-20 | 2014-01-23 | University-Industry Cooperation Group Of Kyung Hee University | Novel peptide tag and uses thereof |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR093387A1 (es) | 2012-11-06 | 2015-06-03 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
CN104173275A (zh) * | 2013-05-21 | 2014-12-03 | 深圳翰宇药业股份有限公司 | 度拉鲁肽注射剂及其制备方法 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
CN104293834B (zh) * | 2014-10-11 | 2018-03-23 | 上海兴迪金生物技术有限公司 | GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
DK3257524T3 (da) * | 2015-02-11 | 2020-11-23 | Gmax Biopharm Llc | Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
CN107661288A (zh) * | 2016-07-29 | 2018-02-06 | 江苏泰康生物医药有限公司 | 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备 |
WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
CN108210890A (zh) * | 2016-12-09 | 2018-06-29 | 江苏泰康生物医药有限公司 | 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂 |
GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
HUE063776T2 (hu) | 2017-06-01 | 2024-01-28 | Lilly Co Eli | Dulaglutid krónikus vesebetegség kezelésére |
BR112020002871A2 (pt) * | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
CN111356472A (zh) * | 2017-11-21 | 2020-06-30 | 伊莱利利公司 | 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 |
CN109836503B (zh) * | 2017-11-24 | 2022-09-16 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
WO2020190591A1 (en) | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
GB201917723D0 (en) * | 2019-12-04 | 2020-01-15 | Nv Rose Llc | Stable liquid formulations of glucagon-like peptide 1 or analogues thereof |
KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
CN114053217B (zh) * | 2020-08-03 | 2023-04-18 | 华兰生物工程股份有限公司 | 一种Exendin-4-Fc融合蛋白注射制剂及其制备方法 |
CN112494658A (zh) * | 2020-12-04 | 2021-03-16 | 苏桥生物(苏州)有限公司 | 一种稳定的Fc融合蛋白制剂 |
CN114685644A (zh) | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
CN117616037A (zh) | 2021-07-06 | 2024-02-27 | 苏州康宁杰瑞生物科技有限公司 | 融合蛋白及其应用 |
CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101044162B (zh) * | 2004-12-22 | 2010-10-27 | 伊莱利利公司 | Glp-1类似物融合蛋白质制剂 |
-
2008
- 2008-07-09 EA EA201070121A patent/EA201070121A1/ru unknown
- 2008-07-09 RS RS20110188A patent/RS52378B/en unknown
- 2008-07-09 NZ NZ582480A patent/NZ582480A/en unknown
- 2008-07-09 AU AU2008275180A patent/AU2008275180A1/en not_active Abandoned
- 2008-07-09 MX MX2010000380A patent/MX2010000380A/es active IP Right Grant
- 2008-07-09 EP EP08772467A patent/EP2175834B8/en active Active
- 2008-07-09 BR BRPI0813699-8A patent/BRPI0813699B1/pt active IP Right Grant
- 2008-07-09 DE DE602008005155T patent/DE602008005155D1/de active Active
- 2008-07-09 JP JP2010516211A patent/JP2010533197A/ja not_active Withdrawn
- 2008-07-09 WO PCT/US2008/069473 patent/WO2009009562A2/en active Application Filing
- 2008-07-09 KR KR1020107000435A patent/KR20100020516A/ko not_active Application Discontinuation
- 2008-07-09 CN CN200880023539A patent/CN101730523A/zh active Pending
- 2008-07-09 UA UAA201000210A patent/UA97673C2/ru unknown
- 2008-07-09 AT AT08772467T patent/ATE499088T1/de not_active IP Right Cessation
- 2008-07-09 CA CA2691695A patent/CA2691695C/en active Active
- 2008-07-09 US US12/665,053 patent/US20100196405A1/en not_active Abandoned
-
2010
- 2010-01-08 ZA ZA2010/00149A patent/ZA201000149B/en unknown
- 2010-08-13 HK HK10107722.8A patent/HK1141237A1/xx unknown
-
2011
- 2011-04-04 HR HR20110242T patent/HRP20110242T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DE602008005155D1 (de) | 2011-04-07 |
EP2175834A2 (en) | 2010-04-21 |
ATE499088T1 (de) | 2011-03-15 |
EP2175834B1 (en) | 2011-02-23 |
RS52378B (en) | 2012-12-31 |
MX2010000380A (es) | 2010-03-29 |
BRPI0813699B1 (pt) | 2021-06-22 |
ZA201000149B (en) | 2011-04-28 |
AU2008275180A1 (en) | 2009-01-15 |
CN101730523A (zh) | 2010-06-09 |
EP2175834B8 (en) | 2012-08-22 |
JP2010533197A (ja) | 2010-10-21 |
NZ582480A (en) | 2011-03-31 |
WO2009009562A2 (en) | 2009-01-15 |
UA97673C2 (ru) | 2012-03-12 |
US20100196405A1 (en) | 2010-08-05 |
WO2009009562A3 (en) | 2009-07-09 |
HK1141237A1 (en) | 2010-11-05 |
CA2691695A1 (en) | 2009-01-15 |
KR20100020516A (ko) | 2010-02-22 |
EA201070121A1 (ru) | 2010-06-30 |
BRPI0813699A2 (pt) | 2014-12-30 |
CA2691695C (en) | 2014-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
AR069989A1 (es) | Formulaciones de vwf recombinantes | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
BRPI0514420A (pt) | peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo | |
RU2009116531A (ru) | Способ лечения остеопороза и используемая в нем композиция | |
JP2012523438A5 (ru) | ||
WO2003093299A3 (en) | Insulin-associated peptides with effects on cerebral health | |
ES2689781T3 (es) | Angiotensina en el tratamiento de afecciones cerebrales | |
PE20091715A1 (es) | Variantes de igf-i pegiladas y composiciones que las contienen | |
RU2008102928A (ru) | Лечение инфекций, вызванных грибками и/или простейшими одноклеточными организмами | |
EA201070315A1 (ru) | Жидкая лекарственная форма конъюгата | |
EA200900095A1 (ru) | Лекарственные формы бифосфонатов для ингаляции и способы их применения | |
JP2014504601A5 (ru) | ||
DK2024387T3 (da) | Peptidsubstans, der forstærker kapillær modstand, farmaceutisk komposition med dens base og fremgangsmåde til applicering deraf | |
RU2011133224A (ru) | Новые фармацевтические композиции | |
EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
US8012935B2 (en) | Synthetic peptides and methods for treating cancer invasion and metastasis | |
ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
KR20220044947A (ko) | 진균 감염의 치료를 위한 조성물 및 방법(compositions and methods for treatment of fungal infections) | |
WO2021081110A2 (en) | Peptides and use thereof | |
MX2022008748A (es) | Administración oral de péptidos. | |
RU2010139769A (ru) | Фармацевтическая композиция для трансназального введения | |
EP1758923B8 (en) | Peptide substance restoring myocardium function |